Twist Bioscience (NASDAQ:TWST) Coverage Initiated at Wolfe Research

Analysts at Wolfe Research started coverage on shares of Twist Bioscience (NASDAQ:TWST) in a research note issued on Friday. The firm set an “outperform” rating and a $60.00 price target on the stock. Wolfe Research’s price objective indicates a potential upside of 26.61% from the company’s current price.

Several other research analysts have also recently weighed in on the company. TD Cowen restated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Leerink Partners upped their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Barclays reduced their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. Finally, Evercore ISI lifted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Stock Down 3.0 %

Shares of TWST opened at $47.39 on Friday. The company has a market capitalization of $2.81 billion, a P/E ratio of -13.16 and a beta of 1.82. Twist Bioscience has a twelve month low of $27.41 and a twelve month high of $60.90. The firm has a 50 day moving average of $44.85 and a 200 day moving average of $46.60.

Insider Activity

In other Twist Bioscience news, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the transaction, the chief accounting officer now owns 45,620 shares of the company’s stock, valued at $2,034,652. The trade was a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 659 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $27,388.04. Following the completion of the sale, the insider now directly owns 94,481 shares of the company’s stock, valued at approximately $3,926,630.36. This trade represents a 0.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 101,787 shares of company stock valued at $4,584,508 in the last 90 days. Company insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors have recently bought and sold shares of TWST. CWM LLC boosted its stake in shares of Twist Bioscience by 27.4% in the second quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after acquiring an additional 524 shares during the period. Blue Trust Inc. boosted its stake in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the period. Nisa Investment Advisors LLC grew its holdings in Twist Bioscience by 31.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after buying an additional 546 shares in the last quarter. EdgeRock Capital LLC bought a new stake in shares of Twist Bioscience during the second quarter valued at approximately $43,000. Finally, Calamos Advisors LLC purchased a new position in shares of Twist Bioscience in the second quarter worth $281,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.